Reverse Bioengineering

Reverse Bioengineering is a private regenerative medicine and longevity-focused biotechnology company developing AgeX-originated induced Tissue Regeneration (iTR) technology. The company was formed to develop and commercialize iTR, a platform intended to partially reprogram cells to a more youthful state and restore regenerative capacity in adult tissues. Its work appears to center on broad platform and patent development rather than a disclosed, conventional named clinical pipeline, with applications spanning aging, tissue regeneration, and potentially cancer biology. Reverse Bioengineering has historically operated within the AgeX/Serina/UniverXome corporate structure and has been associated with Michael D. West and other AgeX leadership. Available public information indicates the company remains at a preclinical stage.